PURE Bioscience Appoints New CEO
2013年9月10日 - 9:30PM
Marketwired
PURE Bioscience, Inc. (OTCQB: PURE), creator
of the patented silver dihydrogen citrate (SDC) antimicrobial,
today announced the appointment of Hank Lambert as its new Chief
Executive Officer. Mr. Lambert replaces the interim CEO, Dave
Pfanzelter, who remains as Chairman of the Board. The company
reported that the management change is part of its previously
announced reorganization establishing new and experienced
leadership focused on commercialization of SDC technology in the
food industry as a unique and proprietary antimicrobial agent to
protect consumer safety against various pathogens.
Mr. Lambert, who will also serve as a company director, is an
accomplished food industry and consumer products executive with
broad management skills, including strategic planning and business
development, go-to-market execution, business integration and food
safety. With over 35 years of industry experience, Mr. Lambert has
established a proven track record of growing both revenues and
earnings at public and private companies such as Heublein Inc., RJ
Reynolds, Nabisco, Inc. and Pinnacle Foods. Mr. Lambert most
recently served as the General Manager, Global Food and Water
Businesses, at UL LLC (Underwriters Laboratories), and has held
various business unit leadership positions servicing the
foodservice and leading consumer food brands markets. Mr. Lambert
has also served on boards and as a member of various food industry
associations, including the International Foodservice Manufacturers
Association (IFMA), Institute of Food Technologists and Safe Supply
of Affordable Food Everywhere (SSAFE).
"Having spent my career in the food, foodservice and, most
recently, food safety industries, I am well aware of the growing
market need for a proven solution such as PURE's SDC-technology
that delivers superior, broad-spectrum antimicrobial efficacy,"
said Hank Lambert, Chief Executive Officer. "I am very excited
about the opportunity to lead and drive customer adoption of PURE's
safe and effective product solutions addressing the ever increasing
market requirements for improved food safety for consumers and the
environment."
"We are pleased to recruit a food industry executive of such
business acumen, caliber and accomplishments as Hank Lambert. His
reputation as a goal-driven leader fits our requirements for
laser-focused discipline and experience to drive the future
commercial adoption of our SDC-based products into the food safety
marketplace," stated Dave Pfanzelter, Chairman of the Board of
PURE. "This management team is well positioned to drive to market
leadership in delivering new and effective food safety solutions to
our customers in foodservice and food processing."
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based
bioscience products that provide solutions to numerous global
health challenges, including Staph (MRSA) and Carbapenem-resistant
Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high
efficacy/low toxicity bioscience technologies, including its silver
dihydrogen citrate-based antimicrobials, represent innovative
advances in diverse markets and lead today's global trend toward
industry and consumer use of "green" products while providing
competitive advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
Forward-looking Statements
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "expect," "intend," "project" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed initiatives and business plans, acceptance of the
Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new
products and receive regulatory approvals of such products,
competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this
release.
Contact: Investor Relations Tom Hemingway, Redwood
Investment Group 714.927.9118 Peter C. Wulff, CFO & COO Pure
Bioscience, Inc. 619.596.8600 ext.111
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024